Reimbursed Care Access in Kiribati
Kiribati regulates controlled substances under domestic Dangerous Drugs legislation (Dangerous Drugs Ordinance 1948 and related amendments) administered via the Ministry of Health and Community Affairs; most classical psychedelics (psilocybin, MDMA, DMT, 5‑MeO‑DMT, ibogaine, ayahuasca components, mescaline, 2C‑X) are treated as controlled/ prohibited substances with no routine medical or reimbursed access. Ketamine is used in clinical practice worldwide as an anaesthetic and is listed on the WHO Model List of Essential Medicines, and therefore may be available for authorized medical/anaesthetic use in Kiribati under standard medical supply/import controls, but there is no evidence of national reimbursement programs or specialized psychedelic‑therapy funding in Kiribati. National law references and import/control frameworks for dangerous drugs are the primary legal source for status and access. [https://kiribati.tradeportal.org/regulations/index|Kiribati Trade Portal - Regulations] [https://www.who.int/groups/expert-committee-on-selection-and-use-of-essential-medicines/essential-medicines-lists|WHO Model List of Essential Medicines]
Psilocybin
Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. #
MDMA
Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. #
Esketamine
Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no public evidence of a national registration, reimbursement, or funded access program for esketamine (Spravato) in Kiribati; modern specialty psychiatric medicines of this type are not part of reported national essential medicines lists or known national reimbursement schemes. # #
Ketamine
Ketamine is widely recognised internationally as an essential injectable anaesthetic and analgesic and is included on the WHO Model List of Essential Medicines; that international designation supports its legitimate medical/anaesthetic use in low‑resource health systems and underpins importation and authorised clinical use where local health services provide anaesthesia. #
In Kiribati the primary legal and regulatory framework for controlled substances and their importation/supply is the Dangerous Drugs legislation administered through the Ministry of Health and Community Affairs; this framework permits authorised medical use of pharmaceutical agents under regulated supply and prescription pathways while prohibiting unauthorised possession or recreational use. Practical implications: ketamine is plausibly available and used within hospital/clinical settings in Kiribati for anaesthesia/analgesia under normal medical controls, but there is no publicly available evidence of a national reimbursement program specifically funding ketamine for off‑label psychiatric (psychedelic‑assisted) indications, nor of structured psychedelic‑therapy clinics or state funding for ketamine‑assisted psychotherapy. Local procurement, storage, prescription and dispensing would be governed by the Ministry’s regulations and import controls. # #
If a clinician in Kiribati wished to use ketamine off‑label for psychiatric indications this would be an institutional/ clinician decision subject to national medicines regulation and facility governance; reimbursement (public or private) is unlikely in the absence of formal national guidance or funded programs and would typically be handled as an individual clinical expense or via external funding arrangements.
DMT
Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. (Note: ayahuasca brews contain DMT, but the plant brew itself is likewise controlled in practice because DMT is scheduled.) #
5-MeO-DMT
Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. #
Ibogaine
Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. #
Ayahuasca
Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. (Because DMT—ayahuasca’s primary psychoactive constituent—is controlled, ayahuasca‑related preparation and use is likewise restricted.) #
Mescaline
Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. (Peyote/indigenous sacramental exemptions common elsewhere are not documented as legal exceptions under Kiribati law.) #
2C-X
Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. #